Naltrexone is a drug that is used in some countries as part of addiction therapy for alcohol and opioid addiction.
Low-dose Naltrexone binds to specific receptors (opioid receptors), causing the body to produce short-acting opioids (met-enkephalin). These substances can block the growth of cancer cells while increasing the activity of the immune cells.
Low-dose Naltrexone also activates genes that activate a kind of suicide program in the cancer cell. As a result, the cancer cell destroys itself. Usually, every cell has a suicide program, which is activated when it has become too old or becomes ill. This process is often deactivated in cancer cells.
Low-dose Naltrexone also increases sensitivity to chemotherapy. Studies show that certain chemotherapies work better if Naltrexone has been given before.
According to studies, Naltrexone shows positive effects in the following types of cancer: Pancreatic cancer, colon cancer, lymphoma, breast cancer, and ovarian cancer.
Experienced therapists can successfully use Naltrexone as a supportive method for certain types of cancer. The low-dose intake is well-tolerated.